HSE begins talks on CF drug Orkambi
News relief to patients with cystic fibrosis and families
Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.
The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.
The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
Analysis: Variants and vaccines make projecting path of virus more complex
While the vaccine rollout should reduce the number of new Covid-19 cases, the increased transmissibility of the new variant mean progress in suppressing the virus has slowed
HSE’s latest private hospitals Covid deal estimated to cost €47 million a month
HSE considers ending surge capacity arrangements with private hospitals as number of Covid-19 hospitalisations falls
Key public health posts remain vacant
Frustrated doctors snub HSE jobs as talks over the long-promised consultant contract stall
Breakdown of HSE’s €1.6 billion war chest to fight Covid-19
The National Service Plan shows that €200m of the €1.6bn allocated to fighting the pandemic is to be spent on the rollout of vaccinations
